Nabati et al. [48] in their single-blind RCT, including 89 women with newly diagnosed breast cancer, showed that rosuvastatin (20 mg) given 24 h before the first cycle of DOXO and continued for 6 months in HER2-positive breast cancer patients also treated with trastuzumab reduced the decline in LVEF, levels of Hs-cTnI and IL-6 at 3 and 6 months, and MPO at 6 months (intergroup p = 0.012). The gene discussed is ERBB2; the disease is breast cancer.